# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Matt O'Brien upgrades Globus Medical (NYSE:GMED) from Neutral to Overweight and raises the price t...
Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $83 to ...
Globus Medical reported quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 57 cents by 26.32...
BTIG analyst Ryan Zimmerman maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $60 to $63.
Piper Sandler analyst Matt O'Brien maintains Globus Medical (NYSE:GMED) with a Neutral and raises the price target from ...